Oxaliplatin
- Generic Name
- Oxaliplatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N2O4Pt
- CAS Number
- 61825-94-3
- Unique Ingredient Identifier
- 04ZR38536J
- Background
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemic...
- Indication
Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.
- Associated Conditions
- Advanced Colorectal Cancer, Stage III Colon Cancer
- Associated Therapies
- -
Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-05-25
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 59
- Registration Number
- NCT00004190
- Locations
- 🇺🇸
CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States
🇺🇸CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States
🇺🇸CCOP - Sioux Community Cancer Consortium, Sioux Falls, South Dakota, United States
Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2004-05-21
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 38
- Registration Number
- NCT00004126
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT00003427
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-04-14
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 44
- Registration Number
- NCT00003834
- Locations
- 🇺🇸
CCOP - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸CCOP - Duluth, Duluth, Minnesota, United States
🇺🇸CentraCare Clinic, Saint Cloud, Minnesota, United States
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2004-04-12
- Last Posted Date
- 2011-03-28
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT00004102
- Locations
- 🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
Oxaliplatin in Treating Patients With Advanced Cancer Plus Liver Dysfunction
- Conditions
- First Posted Date
- 2004-04-12
- Last Posted Date
- 2010-01-06
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT00005077
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Walter Reed Army Medical Center, Washington, District of Columbia, United States
Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 14
- Registration Number
- NCT00080951
Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 46
- Registration Number
- NCT00080990
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
OSI-7904L and Oxaliplatin in Treating Patients With Refractory or Recurrent Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2013-06-12
- Target Recruit Count
- 15
- Registration Number
- NCT00081237
- Locations
- 🇬🇧
Christie Hospital N.H.S. Trust, Manchester, England, United Kingdom
🇩🇪Medizinische Hochschule Hannover, Hannover, Germany
Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2020-02-27
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 146
- Registration Number
- NCT00081289
- Locations
- 🇺🇸
Baptist-South Miami Regional Cancer Program, Miami, Florida, United States
🇺🇸University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸Ingalls Cancer Care Center at Ingalls Memorial Hospital, Harvey, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.